Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aryan Borole

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Journal of Orthopaedic Surgery & Traumatology : Orthopedie Traumatologie|November 3, 2025
Patients with prior anterior shoulder instability have a higher risk of prosthetic dislocation and revision surgery after total shoulder arthroplasty: a cohort studyPeter Boufadel, Mohammad Daher, Aryan Borole, et al.
Cureus|February 25, 2026
Pain After Brachial Plexus Injury Surgery: Variability in ReportingAnna Zakusylo, Aryan Borole, Evan Lobato, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Journal of Orthopaedic Surgery & Traumatology : Orthopedie Traumatologie|November 3, 2025
Patients with prior anterior shoulder instability have a higher risk of prosthetic dislocation and revision surgery after total shoulder arthroplasty: a cohort studyPeter Boufadel, Mohammad Daher, Aryan Borole, et al.
Cureus|February 25, 2026
Pain After Brachial Plexus Injury Surgery: Variability in ReportingAnna Zakusylo, Aryan Borole, Evan Lobato, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Pageof 2